UW-Madison researchers have developed HeLa cell-adapted Rhinovirus-C (RV-C) variants that induce a strong cytopathic effect and replicate vigorously in HeLa-E8 cells. The inventors had previously show...
Learn More

UW-Madison researchers have developed a new combination adjuvant composition (dubbed QTAP) that combines two safe adjuvants (Quil-A and DOTAP) using a nanoparticle preparation protocol developed by th...
Learn More

UW-Madison researchers have identified new mutations that promote replication of influenza A viruses to high titers in embryonated chicken eggs and would therefore increase the manufacturing yield for...
Learn More

UW-Madison researchers have developed methods for making and using modified influenza gene products, alone or in combination, to inhibit WT virus replication, to serve as immunostimulatory agents, or ...
Learn More

UW-Madison researchers, in collaboration with a professor from the University of Missouri, propose using the cryptic lineages (4-24 amino acid substitutions) of the SARS-CoV-2 spike protein sequence t...
Learn More

UW-Madison researchers have developed a SARS-CoV-2 live-attenuated vaccine virus based on the original Wuhan genome but lacking the envelope (E) open reading frame. This vaccine virus replicates effic...
Learn More

UW-Madison researchers have developed a series of mutant influenza B viruses that incorporate mutations in the HA1 protein that cause the virus to react with sera generated via exposure to the opposit...
Learn More

The present invention relates to novel IBV vaccines containing novel modified S and N antigens from avian coronaviruses. The modifications include: S has a modified transmembrane domain for better sec...
Learn More

The present invention relates to a novel bivalent coronavirus/influenza virus vaccine (called CoroFlu). The vaccine comprises a coronavirus antigen (a secreted version of the spike (S) protein of SARS...
Learn More

UW-Madison researchers successfully developed and demonstrated improved mRNA stabilization techniques that leverage mineral coatings. In short, the inventors stabilized mRNA complexes on mineral coate...
Learn More

UW-Madison researchers have isolated and characterized a BA.2 strain of the Omicron variant of SARS-CoV-2.
Learn More

UW-Madison researchers have isolated and characterized a BA.1 strain of the Omicron variant of SARS-CoV-2.
Learn More

UW – Madison researchers have determined that SARS-CoV-2 infection induces antibodies against both structural and non-structural proteins and they identified epitopes in the SARS-CoV-2 membrane prot...
Learn More

The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated DNA vaccine compositions and viral vaccine compositions that encode a SARs-CoV-2 spike (S) protein, a SARs-CoV-2 nucleocaps...
Learn More

The invention provides a vaccine comprising a recombinant biologically contained filovirus and methods of making and using those viruses.
Learn More

Ebola Virus Disease (EVD) is a severe and highly fatal hemorrhagic fever that affects humans and other mammals. It is caused by the Ebola virus, a single-stranded RNA virus that encodes seven structur...
Learn More

Most influenza vaccines are produced in embryonated chicken eggs, but increasingly influenza vaccines are produced in other systems. MDCK (Madin-Darby Canine Kidney) cells are one of two mammalian cel...
Learn More

Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non­toxic tetanus toxin varia...
Learn More

The present disclosure relates to vims-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial vims (RSV) infection. Specifically, the disclosure provides vi...
Learn More

A method to prepare recombinant influenza viruses comprising a mutant M2 protein which has a deletion of two or more residues in the cytoplasmic tail and is attenuated in vivo, is provided, as well th...
Learn More

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isola...
Learn More

A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.
Learn More

Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.
Learn More

It is disclosed herein that (a) an anti-tumor DNA vaccine delivered using a MIP DNA vector is a less effective tumor treatment than the corresponding anti-tumor DNA vaccine delivered using a conventio...
Learn More